Hubei Provincial Cancer Hospital

Wuhan, China

Hubei Provincial Cancer Hospital

Wuhan, China

Time filter

Source Type

Weng G.-L.,Hubei Provincial Cancer Hospital | Huang J.-G.,Hubei Provincial Cancer Hospital | Chu D.,Hubei Provincial Cancer Hospital | Mei L.-L.,Hubei Provincial Cancer Hospital | And 2 more authors.
Journal of Interventional Radiology (China) | Year: 2014

Objective: To investigate the detection rate of contrast-enhanced ultrasound (CEUS) for iso - echo liver cancers, and to evaluate the application of CEUS in treating iso - echo liver cancers with radiofrequency ablation (RFA).Methods: A total of 27 patients with liver cancers (31 lesions in total) were enrolled in this study. Of the 27 patients, hepatocellular carcinoma (HCC) was seen in 11 (11 lesions) and hepatic metastasis in 16 (20 lesions). In all patients the diagnosis was detected by contrast-enhanced CT or contrast-enhanced MRI and was clinically confirmed. Under real-time CEUS guidance, RFA was carried out for all the 31 lesions. The ablated extent was evaluated by CEUS, and CEUS findings were used to guide the further treatment.Results: All 31 lesions were detected by CEUS and were treated with RFA. No serious complications occurred after RFA. Both CEUS and CECT performed one month after RFA showed that complete tumor necrosis was seen in all the 31 lesions. After RFA the serum AFP levels in all 11 HCC patients fell to normal range, and the serum CEA, CA-199 as well as CA-153 levels in patients with hepatic metastasis decreased significantly (P < 0.01).Conclusion: CEUS can markedly increase the detection rate of iso-echo liver cancers. Besides, CEUS plays an important role in guiding the performance of RFA for iso - echo liver lesions.


Xu G.,Chinese Academy of Sciences | Lu T.,Sun Yat Sen University | Hong M.,Sun Yat Sen University | Pan J.,Fujian Medical University | And 19 more authors.
Journal of Radiation Oncology | Year: 2013

With the advances of diagnostic imaging and radiation therapy technology, the limitations of the Chinese 1992 staging system for nasopharyngeal carcinoma (NPC) become obvious, and the revision of this system was clearly needed. On December 16, 2008, the Chinese Committee for Staging of Nasopharyngeal Carcinoma (CCSNPC) was inaugurated in Guangzhou, China, with the purpose of establishing a platform for the study of the Chinese staging system and ensuring the continuity of the work of NPC staging research. Data from published studies on staging of NPC were collected and reviewed. After extensive evaluation and discussion, the Chinese 2008 staging system for NPC, which was a consensus based on evidence-based medicine and revisions made on the Chinese 1992 staging system, was recommended by CCSNPC. Changes of the staging system including emphasizing the status of MRI in diagnosis and staging; classification of parapharyngeal involvement, cranial nerve involvement, and retropharyngeal lymph node involvement; and T classification in the new system were simplified as well. CCSNPC also proposed a new criterion of the N category. This review discusses the rationale and bases of our primary revisions of this system and proposes an updated system, named the Chinese 2008 staging system for NPC. Further investigations are needed to confirm the effectiveness as well as to provide basis for further improvement of this system. © 2013 Springer-Verlag Berlin Heidelberg.


Yin T.,Hubei Provincial Cancer Hospital | Cui D.-S.,Hubei Provincial Cancer Hospital | Xiong Z.-G.,Hubei Provincial Cancer Hospital | Wei S.-Z.,Hubei Provincial Cancer Hospital
International Journal of Clinical and Experimental Medicine | Year: 2015

Objective: This study aims to investigate the clinical synchronization of the neoadjuvant chemoradiation (NC) and the laparoscopic total mesorectal excision (TME) in the treatment of locally aggressive colorectal cancer (LACC). Methods: 92 LACC patients were selected for the research, among who 46 cases, who were performed the synchronized NC, were divided into the treatment group, after having rest for 4-6 weeks after the treatment, the 40 patients of the treatment group, who were performed the laparoscopic surgery, formed the laparoscopy group. The rest 46 patients were divided into the control group, who were performed the conventional treatment. The intraoperative conditions, postoperative recoveries, postoperative complications and recurrence rates of the two groups were compared. Results: The stage-declining rate of the treatment group was 67.3%, and the surgical resection rate, anal preservation rate and postoperative complications were 86.9%, 69.6% and 26%, respectively, which were significantly higher than the control group; while the long-term recurrence rate significantly decreased to 21.7%, and the difference was statistically significant (P<0.05). Conclusion: The NC could effectively achieve the stage-declining purpose against the LACC, improve the resection rate and reduce the postoperative recurrence rate. © 2015, E-Century Publishing Corporation. All rights reserved.


Chen S.-P.,Sun Yat Sen University | Liu B.-X.,Guangzhou hospital of traditional Chinese medicine | Xu J.,Guangdong Provincial Peoples Hospital | Pei X.-F.,Sun Yat Sen University | And 3 more authors.
BMC Cancer | Year: 2015

Background: Increasing evidence indicates that Epithelial-mesenchymal transition (EMT) can be regulated by microRNAs (miRNAs). MiR-449a is a liver abundant miRNA. However, the role of miR-449a in the metastasis of hepatocellular carcinoma (HCC) remains largely unknown. Methods: The expression levels of miR-449a were first examined in HCC cell lines and tumour tissues by real-time PCR. The in vitro and in vivo functional effect and underlying molecular mechanisms of miR-449a were examined further. Results: In the present study, we found that miR-449a was significantly decreased in HCC cells and tissues, especially in those with the portal vein tumor thrombus. In HCC cell lines, stable overexpression of miR-449a was sufficient to inhibit cell motility in vitro, and pulmonary metastasis in vivo. In addition, ectopic overexpression of miR-449a in HCC cells promoted the expression of epithelial markers and reduced the levels of mesenchymal markers. Further studies revealed that the reintroduction of miR-449a attenuated the downstream signaling of Met, and consequently reduced the accumulation of Snail in cell nucleus by targeting the 3'-untranslated regions (3'-UTR) of FOS and Met. Conclusions: Our data highlight an important role of miR-449a in the molecular etiology of HCC, and implicate the potential application of miR-449a in cancer therapy. © 2015 Chen et al.


PubMed | Hubei Provincial Cancer Hospital, Guangzhou hospital of traditional Chinese medicine, Sun Yat Sen University and Guangdong Provincial Peoples Hospital
Type: | Journal: BMC cancer | Year: 2015

Increasing evidence indicates that Epithelial-mesenchymal transition (EMT) can be regulated by microRNAs (miRNAs). MiR-449a is a liver abundant miRNA. However, the role of miR-449a in the metastasis of hepatocellular carcinoma (HCC) remains largely unknown.The expression levels of miR-449a were first examined in HCC cell lines and tumour tissues by real-time PCR. The in vitro and in vivo functional effect and underlying molecular mechanisms of miR-449a were examined further.In the present study, we found that miR-449a was significantly decreased in HCC cells and tissues, especially in those with the portal vein tumor thrombus. In HCC cell lines, stable overexpression of miR-449a was sufficient to inhibit cell motility in vitro, and pulmonary metastasis in vivo. In addition, ectopic overexpression of miR-449a in HCC cells promoted the expression of epithelial markers and reduced the levels of mesenchymal markers. Further studies revealed that the reintroduction of miR-449a attenuated the downstream signaling of Met, and consequently reduced the accumulation of Snail in cell nucleus by targeting the 3-untranslated regions (3-UTR) of FOS and Met.Our data highlight an important role of miR-449a in the molecular etiology of HCC, and implicate the potential application of miR-449a in cancer therapy.

Loading Hubei Provincial Cancer Hospital collaborators
Loading Hubei Provincial Cancer Hospital collaborators